MSB 1.64% 93.0¢ mesoblast limited

Overwhelming efficacy - the stats required, page-8

  1. 108 Posts.
    lightbulb Created with Sketch. 94
    Great post @kervio, this is a continuation of our conversation the other day (you have explained beautifully).

    The question the analysis raises (or unknown at this point) is whether or not the SOC improvements in survival rates will also be seen in the Rem-L group?

    • Based on Mt Sinai I think the figs were 83% survival (17% mortality) for Rem-L.
    • The SOC has moved from 88% mortality to 35% mortality
    • If we get only (for example) a 25% improvement in our mortality rate due to the general SOC improvement
    • The new (Rem-L) mortality percentage would 12.75% (down from 17%) ie only 9 deaths in 68 achieving the p<0.0001 (or overwhelming efficacy at the 45% readout)

    I don't know whether the general improvements in SOC would translate into an improvement in both groups, it is however, a potential upside for earlier overwhelming efficacy.

    Maybe someone else could answer that?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
93.0¢
Change
0.015(1.64%)
Mkt cap ! $1.061B
Open High Low Value Volume
92.5¢ 95.0¢ 89.0¢ $7.902M 8.522M

Buyers (Bids)

No. Vol. Price($)
2 2945 92.5¢
 

Sellers (Offers)

Price($) Vol. No.
93.0¢ 40422 4
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
93.0¢
  Change
0.015 ( 2.54 %)
Open High Low Volume
92.0¢ 95.0¢ 89.5¢ 2254102
Last updated 15.59pm 26/04/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.